

REVIEW

**OPEN ACCESS**  
Full open access to this and thousands of other papers at <http://www.la-press.com>.

## Hereditary Inclusion Body Myopathy (HIBM2)

Chris M. Jay<sup>1</sup>, Nick Levonyak<sup>2</sup>, Gregory Nemunaitis<sup>2,3</sup>, Phillip B. Maples<sup>1</sup> and John Nemunaitis<sup>1,2,4,5</sup>

<sup>1</sup>Gradalis, Inc., <sup>2</sup>Mary Crowley Cancer Research Centers, Dallas, TX, USA. <sup>3</sup>MetroHealth Medical Center, Cleveland, OH, USA. <sup>4</sup>Texas Oncology, PA, USA. <sup>5</sup>Baylor Sammons Cancer Center, Dallas, TX, USA.

Email: [jnemunaitis@marycrowley.org](mailto:jnemunaitis@marycrowley.org)

---

**Abstract:** Hereditary inclusion body myopathy type 2 (HIBM2) is a myopathy characterized by progressive muscle weakness with early adult onset. The disease is the result of a recessive mutation in the Glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase gene (GNE), which results in reduced enzyme function and sialic acid levels. A majority of individuals with HIBM2 are from Iranian-Jewish or Japanese decent, but isolated cases have been identified world wide. This article reviews the diagnostic criteria for HIBM2. Current research with a highlight on the biology of the disease and the role of GNE in the sialic acid pathway are assessed. Finally, therapeutic investigations and animal models are discussed with a focus on future studies to better understand the pathology of Hereditary Inclusion Body Myopathy and move therapeutic agents towards clinical trials.

**Keywords:** HIBM2, GNE, sialic acid, myopathy, neuromuscular

---

*Gene Regulation and Systems Biology* 2009:3 181–190

This article is available from <http://www.la-press.com>.

© the authors, licensee Libertas Academica Ltd.

This is an open access article distributed under the terms of the Creative Commons Attribution License (<http://www.creativecommons.org/licenses/by/2.0>) which permits unrestricted use, distribution and reproduction provided the original work is properly cited.



## Introduction to HIBM2

HIBM2 is a myopathy that was first recognized in individuals of Iranian-Jewish descent that is clinically manifest by progressive muscle weakness and genetically transmitted in an autosomal-recessive manner. There are a number of myopathies which cause progressive muscle weakness. HIBM2 is unique in that it is clinically characterized by early adult onset, ethnic predisposition, and quadriceps sparing. HIBM2 is histologically characterized by atrophic muscle fibers with rimmed vacuoles and filamentous inclusions in the absence of inflammatory cells.<sup>1-3</sup>

Only 220 (<http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=ibm>) cases of HIBM2 have been reported worldwide, although more cases may be undiagnosed. The vast majority are from Iranian-Jewish descent. In the Iranian-Jewish population the frequency is greater than 1 in every 1500 individuals. This syndrome has also been described in Japan where the disorder is often referred to as Distal Myopathy with Rimmed Vacuoles (DMRV).<sup>4</sup>

Patients of American, Afghanistan, Iraqi-Kurdish, Irish, German, Mexican, African-American, possibly Egyptian communities, and Italian descents have also been identified.<sup>2,5,6</sup>

HIBM2 is an autosomal recessive disorder and, therefore, an affected allele must be inherited from both parents in order for a child to phenotypically develop the syndrome. These mutated genes (either homozygous or heterozygous mutations) are then expressed as the hypofunctional enzyme, Glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase (GNE), which catalyzes the first two reactions in the production of sialic acid. HIBM-associated *GNE* mutations have been shown to reduce sialic acid production.<sup>7,8</sup> The pathologic mechanism for muscle degeneration in HIBM2 remains unknown but evidence suggests, that proper folding, stabilization, and function of skeletal muscle glycoproteins require muscle fiber sialylation.<sup>9-12</sup> *GNE* mutations resulting in hyposialylation of muscle glycoproteins appear to contribute to myofibrillar degeneration and loss of normal muscle function.<sup>9,11,13-16</sup>

The most prevalent mutation in HIBM2 patients of Middle Eastern descent is the missense mutation, M712T, located on exon 12 of the *GNE* gene.<sup>17,18</sup> However, novel mutations (such as the D176V [exon 3] and V572L [exon 9] mutation which is

more common in Japanese patients) have also been discovered in both the epimerase and kinase domains of the *GNE* gene in HIBM2 patients of other ethnic backgrounds.<sup>2,4-6</sup>

This review will summarize diagnostic, molecular, and therapeutic results related to HIBM2.

## Diagnosis

The most common criteria used for identifying HIBM2 are as follows: 1) distal skeletal muscle weakness beginning in the lower legs; 2) selective sparing of the quadriceps; 3) onset in the third to fourth decade of life; 4) a familial history of muscle wasting disorder is not obligatory for the diagnosis; 5) minimal to no elevation in serum creatine kinase (CK); 6) the histologic presence of rimmed vacuoles within muscle fibers in the absence of inflammatory cells; and 7) tubofilamentous inclusions in muscle by electron microscopy. Exceptions have been described; however, they are generally applicable to less than 10% of patients.<sup>18</sup>

One unscrutinized criteria for diagnosis of HIBM2 is the onset in early adulthood. Generally, the disorder becomes apparent anywhere from 20 to 40 years of age. After 2-3 decades, almost complete muscle function is lost in the patient with sparing of the facial, extraocular, bulbar, intercostal and diaphragm muscles.<sup>19</sup> The progressive deterioration of the axial muscles will often leave the patient wheel-chair bound and unable to perform the basic functions of everyday life.

## Molecular Biology

Underproduction of skeletal muscle sialic acid related to dysfunctional *GNE* gene product is the hallmark of HIBM2.<sup>5,9,13,18,20</sup> Sialic acid is the only sugar that bears a net negative charge.<sup>21</sup> This charged sugar provides the terminal carbohydrate on a variety of N-linked and O-linked glycoproteins that mediate cell-cell and protein-protein interactions. Thus, the role as cell surface macromolecules may not be easily mimicked by other biologically available oligosaccharide moieties. More than 40 different sialic acid compounds have been identified with various biological functions. Sialic acids can be found as part of cell surface glycoproteins, glycolipids, gangliosides, and polysaccharides. The sialic acid modifications of cell surface glycoproteins are crucial for cell adhesion

and signal transduction and may result in muscle fiber degeneration.<sup>22,23</sup>

UDP-GlcNAc 2-epimerase activity is rate-limiting for the biosynthesis of sialic acid. The activity of the enzyme can be controlled by allosteric regulation of the downstream product, CMP-sialic acid (Fig. 1).<sup>24</sup> In cardiac muscle, removal of sialic acid produces a large specific increase in sarcolemmal calcium permeability without perturbation of potassium permeability.<sup>12,25,26</sup> Sialic acid accounts for a component of negatively charged sites which, with other acidic mucopolysaccharides, contributes to cationic binding at the surface of the cell. Calcium bound at the surface seems to be of importance in the excitation-contraction (EC) coupling sequence whether as a source of “trigger” calcium for the sarcolemmal system or as a direct activator of the myofilaments. The bound  $\text{Ca}^{++}$  appears to be in rapid equilibrium with free  $\text{Ca}^{++}$  in the vascular and interstitial spaces and is the probable immediate source of the  $\text{Ca}^{++}$  that crosses the sarcolemma. The integrity of the glycocalyx appears to be necessary in the prevention of uncontrolled entry of  $\text{Ca}^{++}$  into the cell.<sup>12,27</sup>

In skeletal muscle, most transmembrane proteins, including voltage-gated sodium channels, are post-translationally modified. Channels are heavily glycosylated, with up to 40% of the molecular weight of the functional sodium channel comprised of sugar molecules. It has been shown that as the sugar residues are removed, sodium channel activity is changed such that a greater depolarization is needed to activate the channel. Thus, channels with lowered glycosylation levels will be less active at a given membrane potential, and the cell likely will be hypo-excitabile.<sup>28</sup>

Loss of GNE activity in HIBM2 is thought to impair sialic acid production and interfere with proper sialylation of glycoconjugates. Sialylation of the voltage-gated sodium channels is critical to maintain proper gating of sodium for effective initiation and propagation of action potentials in nerve and muscle.<sup>29–35</sup> Voltage-gated sodium channels are complex membrane proteins composed of an  $\alpha$  subunit and one or more smaller  $\beta$  subunits.<sup>36–38</sup> Estimates indicate that 15%–40% of the total sodium channel molecular weight is carbohydrate.<sup>39–41</sup> Approximately 40%–45% of the added carbohydrate residues are sialic acid.<sup>40,41</sup> The terminal sialic acid residues are attached to  $\alpha$  and  $\beta$  subunits and in the absence of sialic acid the channel

gating is in the depolarized position.<sup>42–46</sup> The lack of effective action potential transmission results in the failure of nerve and muscle activation.

Voltage-gated sodium channels ( $\text{Na}_v$ ) are responsible for initiation and propagation of nerve, skeletal muscle, and cardiac action potentials.  $\text{Na}_v$  are composed of a pore-forming  $\alpha$ -subunit and often one to several modulating  $\beta$ -subunits. Previous work showed that terminal sialic acid residues are attached to  $\alpha$ -subunits and affect channel gating.<sup>28</sup> Under conditions of reduced sialylation, the  $\beta$ 1-induced gating effect is eliminated. Consistent with this, mutation of  $\beta$ 1 N-glycosylation sites abolish all effects of  $\beta$ 1 on channel gating. Data also suggest an interaction between the cis effect of  $\alpha$ -sialic acids and the trans effect of  $\beta$ 1 sialic acids on channel gating.  $\beta$ 1 sialic acids have no effect on gating of the heavily glycosylated skeletal muscle  $\alpha$ -subunit. However, when glycosylation of the skeletal muscle  $\alpha$ -subunit was reduced through chimeragenesis such that  $\alpha$ -sialic acids did not impact gating,  $\beta$ 1 sialic acids caused a significant hyperpolarizing shift in channel gating. Together, the data indicate that  $\beta$ 1 N-linked sialic acids can modulate  $\text{Na}_v$  gating through an apparent saturating electrostatic mechanism.<sup>46</sup>

Previous studies have shown that the subunits of the  $\text{Na}^+$  channel are modified by glycosylation and the  $\beta$ 1,  $\beta$ 2, brain, and muscle  $\alpha$ -subunits are heavily glycosylated, with up to 40% (eel electroplax  $\alpha$ -subunit)<sup>47</sup> of the mass being carbohydrate. In contrast, the cardiac subunit is only 5% sugar by weight.<sup>48</sup> Sialic acid is a prominent component of the N-linked carbohydrate of the  $\text{Na}^+$  channel. The addition of such a highly charged carbohydrate has predictable effects on the voltage dependence of gating through alteration of the surface charge of the channel protein. Neuraminidase treatment to remove cell surface sialic acid from skeletal muscle channels produced a depolarizing shift of steady-state inactivation.<sup>43</sup> Local surface charge is also significantly influenced by charged amino acid residues which stud the outer mouth of the pore, although the predominant effects in this case are on permeation rather than gating.<sup>49,50</sup>

Co-translational glycosylation is essential for the maintenance of cell surface expression of the  $\text{Na}^+$  channel in neurons and Schwann cells.<sup>51,52</sup> Inhibition of glycosylation by tunicamycin reversibly decreases the number of STX binding sites on



neuroblastoma cells.<sup>53</sup> Tunicamycin also inhibits palmitation, sulphation, and disulphide attachment of the  $\beta$ 2 subunit, preventing the assembly of functional  $\text{Na}^+$  channels.<sup>39</sup>

Studies of HIBM2 patients reveal mutations in the GNE gene associated with glycosylation deficiencies which may lead to defective muscle function. Reduced GNE activity is thought to impair sialic acid production and interfere with proper sialylation of glycoconjugates.<sup>12</sup> The reactivities to lectins are also variable in some myofibers, suggesting that hyposialylation in muscles may contribute to the focal accumulations of autophagic vacuoles and/or amyloid deposits in affected muscle tissue. Although sialic acid dysregulation is likely primary to disease pathogenesis, recent assessments of myoblast cellular sialylation patterns,<sup>14,15</sup> suggest the possible role of other GNE-related contributing mechanisms.<sup>54,55</sup> Eisenberg et al looked at the role of GNE gene and other neighboring genes, such as, clathrin light chainA (CLTA)<sup>56</sup> which is a regulatory element in clathrin gene function, known to be involved in several pathways of lysosomal proteolysis, and, reversion-inducing cysteine-rich protein with Kazal motifs (RECK)<sup>57</sup> which is a membrane-anchored glycoprotein with transformation suppressor activity both located close to the GNE gene.<sup>58</sup> Sequencing of the coding regions of these genes, and LOC64148 and FLJ21343, which also could not be excluded as possible functional candidate genes in HIBM, revealed no disease causing alleles in any of these genes in HIBM families. Although RECK and CLTA are located close to GNE on chromosome 9p12, there was no evidence that these genes contributed to HIBM2.

Neprilysin, also known as neutral endopeptidase (NEP), CD10, and common acute lymphoblastic leukemia antigen (CALLA), is a zinc-dependent metalloprotease enzyme that degrades a number of small secreted peptides, most notably the amyloid beta peptide whose abnormal misfolding and aggregation in neural tissue has been implicated as a cause of Alzheimer's disease. One study found that Neprilysin participates in skeletal muscle regeneration and is accumulated in abnormal muscle fibres of inclusion body myositis.<sup>59</sup> NEP may play an important role during muscle cell differentiation, possibly through regulation, either directly or indirectly, of the insulin-like growth factor I-driven myogenic

programme. However, IGF-1 does not appear to be a contributing factor in HIBM2.<sup>59</sup>

Although sialic acid dysregulation is key to disease pathogenesis, recent assessment of myoblast cellular sialylation in patients suggests the role of other GNE related mechanisms including that of  $\alpha$ -actinin 1.  $\alpha$ -Actinin 1 is one in a group of four  $\alpha$ -actinins and they all play key roles in cell-cell contact sites as well as stress fiber dense regions. There is a direct kinetic relationship between the GNE gene and  $\alpha$ -actinin 1 which could also lead to muscle deterioration along with sialic acid. Calcium has been shown to have a positive effect on  $\alpha$ -actinin.<sup>60</sup>

To investigate the role of mutated GNE enzyme, tissue derived cell cultures from biopsies carrying either kinase or epimerase mutations were created.<sup>14,15</sup> All mutations in the GNE gene caused a reduction in epimerase activity but only the homozygous epimerase mutation actually showed a reduction in sialic acid. However, Penner et al found that recombinant expressed GNE mutants containing either epimerase or kinase mutations had reduced epimerase enzyme activity, with the exception of the most common mutation, M712T, which had normal epimerase activity, but reduced kinase activity.<sup>8</sup> Therefore, the mutations in the two domains do not have the same effect on enzyme activity or sialylation of muscle cells. The sialic acid modifications of cell surface glycoproteins are crucial for cell adhesion and signal transduction and may result in muscle fiber degeneration.<sup>22,23</sup>

Although GNE mutations are widely accepted as the root cause of HIBM2, there are some discussions that GNE plays a role in functions beyond sialic acid synthesis. Upon nocodazole treatment to inhibit intracellular trafficking, GNE was redistributed from the Golgi to the cytoplasm. This suggests that GNE may play a role as a nucleo-cytoplasmic shuttling protein.<sup>61</sup> Salama et al demonstrated in vitro that myoblasts and lymphoblastoid cell lines derived from HIBM2 patients containing the M712T mutation had reduced epimerase activities, but did not display reduced membrane bound sialic acid. However, clinical samples from HIBM2 patients demonstrated clear reduction in sialic acid levels from muscle tissues.<sup>9,11</sup> Savelkoul may have described it best that HIBM2 defects in sialylation may appear gradually and tissues such as muscle, which normally express

low levels of GNE protein, are more sensitive to disruptions in the GNE enzyme and hence reduced sialic acid expression.<sup>62</sup>

GNE is ubiquitously expressed in all tissues, although at relatively different levels in each specific tissue. GNE is expressed at high levels in the liver, and by comparison at relatively low levels in skeletal muscle. Krause et al found that GNE protein is expressed in skeletal muscle at equal levels in HIBM patients and normal control subjects. Furthermore, immunofluorescence detection of GNE did not reveal any mislocalization of GNE in skeletal muscle of HIBM patients. Thus, most in the field conclude that impaired GNE function, not lack of expression, is the key pathogenic factor in HIBM.<sup>63</sup> In fact, Penner et al characterized several different GNE mutations and demonstrated that unique mutations altered activity of GNE enzyme to varying degrees of severity, as assessed by downstream enzyme kinetics of ManNAc phosphorylation using a radiolabeled phosphate assay.<sup>8</sup> Interestingly, all mutations did retain a minimal amount of activity relative to the wild type GNE enzyme.

## Role of GNE in the Sialic Acid Pathway

The GNE gene encodes the bifunctional enzyme UDP-GlcNAc 2 Epimerase/ManNAc Kinase (GNE/MNK). This enzyme is the rate-limiting step which


catalyzes two sequential reactions committed towards sialic acid biosynthesis (Fig. 1). The product of the pathway, cytidine monophosphate-N-Acetylneuraminic Acid (CMP-sialic acid), binds to the allosteric site of the GNE enzyme and inhibits the rate limiting epimerase reaction.

The sialic pathway begins with the glycolysis cycle, which produces UDP-GlcNAc. The GNE/MNK bifunctional enzyme converts the UDP-GlcNAc into ManNAc and then ManNAc-6-P. This sugar is then converted into sialic acid via Neu5Ac-9-P synthase/phosphatase and transported into the nucleus, where CMP-sialic acid synthase adds CMP to Neu5Ac.

CMP-sialic acid leaves the nucleus and is transported to the golgi where sialyltransferase binds sialic acid and glycans to create sialoglycoconjugates. CMP is released during this step and recycled back to the nucleus. Any excess CMP-sialic acid in the cytosol will bind to the regulatory domain of GNE and block further conversion of UDP-GlcNAc into ManNAc. Therefore, the downstream product CMP-sialic acid is able to bind to the auto-regulatory domain of GNE and prevent the overexpression of sialic acid and sialoglycoconjugates.

## Therapeutic Investigation

Currently there is no known effective therapy for the treatment of HIBM2. While other myopathies such



**Figure 1.** Sialic acid pathway. GNE/MNK is the rate limiting step in the pathway. The downstream product, CMP-sialic acid regulates the activity of GNE by allosteric inhibition.



as polymyositis and dermatomyositis respond at least partially to corticosteroids, plasmapheresis/filtration, or other immunosuppressive therapies, there is no or limited evidence of efficacy with these approaches in HIBM2.<sup>64,65</sup> Review of the literature failed to identify clinical trials using steroids and plasmapheresis for the treatment of persons with HIBM2, however the use of intravenous immunoglobulins (IVIG) has been studied. In a double-blind, placebo-controlled trial involving 19 individuals with HIBM2 treated with IVIG conducted in 1997, results suggested that this treatment may have a very short term affect on some patients.<sup>66</sup> In a more recent study conducted in 2007, four HIBM patients were treated with IVIG and each showed improved muscle function throughout the study.<sup>67</sup> However, while these patients showed improved muscle function, there was no evidence to suggest that glycoprotein sialylation was positively effect by the immune globulins. It was postulated that the IVIG would supply sialic acid (IVIG being sialic acid rich). No direct evidence was given to support this. It was not thought that the IVIG was mediating some immune mediated issue. There was no functional benefit observed when the IVIG was combined with prednisone in another study involving 36 patients.<sup>68</sup>

Sialic Acid, ManNAC, or NeuAc replacements, which bypass the defective epimerase and/or kinase related to the GNE mutation, are currently being explored in murine and in vitro experiments and preliminary results show potential improvement in GNE mutated fibroblast function.<sup>7,22,69</sup>

A study conducted in early 2007 provided evidence that a GNE knockout mouse which expressed the human mutated *GNE* gene with D176V mutation ( $Gne^{(-/-)}$  hGNED176V-Tg) developed similar features to human HIBM2 patients. The mice began with just the addition of a Neo cassette that replaced 1.4 kb upstream of exon 3, through 1.4 kb downstream of exon 3, thereby deleting exon 3. However, using this procedure only wild type (WT) and  $GNE^{(+/-)}$  mice survived. However, when  $GNE^{(+/-)}$  mice were crossed with a transgenic mouse that expressed the human mutated GNE with D176V (which is one of the most common mutations), 9% of the offspring were of the desired  $Gne^{(-/-)}$  hGNED176V-Tg.<sup>70</sup>

The sialic acid levels of both the  $Gne^{(-/-)}$  hGNED176V-Tg mice and the WT mice were measured using high-performance liquid chromatography.

Sialic acid levels were measured in the liver, spleen, brain, kidney, muscle, and heart. For WT mice, levels were highest in the liver, spleen, and brain, but the sialic acid levels of the  $Gne^{(-/-)}$  hGNED176V-Tg mice were much lower. In fact, in the liver and kidney, WT mice showed more than five times the amount of sialic acid.  $Gne^{(-/-)}$  hGNED176V-Tg had a third less sialic acid than WT species in the spleen. Overall, it is clear that the  $Gne^{(-/-)}$  hGNED176V-Tg have an overall decrease in sialic acid.<sup>70</sup>

Progression of the disease also seemed to be noticeably similar in the  $Gne^{(-/-)}$  hGNED176V-Tg to human HIBM2 patients. At birth, the  $Gne^{(-/-)}$  hGNED176V-Tg mice were not distinguishable from the other mice, but after 30 weeks of age these mice weighed less than the WT mice. Thirty weeks in the lifetime of a mouse is comparable to the second to third decade onset in human patients. When 12 of the  $Gne^{(-/-)}$  hGNED176V-Tg mice died, 5 (41%) mice had rimmed vacuoles (RVs) in their skeletal muscles which is a key histological characteristic of HIBM2.<sup>70</sup>

Given this finding, characteristic pathological features were then tracked in new litters of  $Gne^{(-/-)}$  hGNED176V-Tg mice. Again, before 30 weeks of age, there was almost no difference observed between the  $Gne^{(-/-)}$  hGNED176V-Tg and their littermates. By 40 weeks of age, fibers begin to appear atrophic and RVs are spotted in scattered fibers. On occasion, inclusion bodies were found in the fibers with or without RVs. Similar to humans, these RVs have been intensely stained with acid phosphatase, indicating that autophagic process is activated.<sup>70</sup>

From these studies, it is quite clear that the  $Gne^{(-/-)}$  hGNED176V-Tg is the closest model to date that resembles human HIBM2 patients both histologically and pathologically. However, there are several differences in the D176V-Tg mouse compared with HIBM2 patients. The mice had a high GNE D176V-Tg mRNA expression in the muscle, possibly due to the promoter used in the study. Also, the quadriceps were preferentially involved in the mice, whereas HIBM2 patients are characterized by quadriceps sparing until late into the disease progression. Finally, some of the GNE D176V-Tg mice died sooner than their littermates for unknown reasons. Studies conducted before had failed to produce a mouse that could actually be tested for treatment because the animals were embryonic lethal.<sup>34</sup>



A research article published in summer 2007 outlines the creation of a  $Gne^{M712T/M712T}$  knockin mouse that was then actually treated using ManNAc feeding as an exploratory therapeutic measure. The mouse was created using a murine targeting vector for homologous recombination in C57BL/6J embryonic stem cells which included the M712T mutation. The neomycin phosphotransferase and thymidine kinase genes were each respectively introduced into the vector as positive and negative selection markers. This entire vector was sequence verified.<sup>71</sup>

As with the previous study, there were non-HIBM2 phenotypes present in the M712T mouse model, along with indicators that these mice showed similar pathology to human HIBM2 patients. Untreated  $Gne^{M712T/M712T}$  pups died by day 3 due to severe glomerular proteinuria. High-magnification examination of the  $Gne^{M712T/M712T}$  kidneys indicated that red blood cell infiltrates in the proximal and distal convoluted tubules and collecting ducts were present in the mutated mice. This renal phenotype is not present in HIBM2 patients.

The second portion of this M712T mouse study was to administer ManNAc to drinking water of pregnant females during gestation and early postnatal nursing of mutant mice. ManNAc is situated in the sialic acid pathway after the regulated rate-limiting GNE step so its metabolism is not subject to feedback inhibition. Given at a concentration of 1 mg/mL, the ManNAc produced no surviving homozygous  $Gne^{M712T/M712T}$  mice out of 51 total offspring. However, when the concentration was increased to 5 mg/mL, 12  $Gne^{M712T/M712T}$  mice (12%) survived beyond P3 out of a total of 102. Of the pups that survived beyond day 3, 17% survived beyond weaning (day 21), when ManNAc treatment was stopped. These surviving mice continued to grow until 3.5 months, but remained smaller than their littermates. No side effects were observed due to the treatment and upon ManNAc treatment. There were less cystic tubular dilations in the cortex and medulla supporting histological improvement in these mice as well. Biochemical analysis also demonstrated improvement in GNE protein expression, PSA-NCAM, and podocalyxin. These results support the evaluation of ManNAc therapy for the treatment of HIBM2.<sup>71</sup>

In another study, GNE gene replacement demonstrated the safety of GNE-lipoplexes administered to

normal mice.<sup>72</sup> A GNE-wt-DNA vector using human GNE cDNA and the pUMVC3 expression vector was constructed and placed in an extensively characterized cationic liposome.<sup>73,74</sup> This vector produced high levels of recombinant GNE protein and subsequent sialic acid in transfected CHO-Lec3 (GNE deficient cell line) cells that produced low levels of sialic acid.<sup>73</sup> The lipoplexes were injected intramuscularly (IM) or intravenously (IV) into BALB/c mice. Single IM injections of the GNE-lipoplex at 40  $\mu$ g DNA did not produce overt toxicity or deaths, indicating that the maximum tolerated dose for IM injection was  $\geq 40$   $\mu$ g DNA. In fact, mice administered with either 10  $\mu$ g or 40  $\mu$ g GNE-lipoplex survived without demonstrating overt signs of toxicity for the observation period of 2 weeks. These findings were supported by 100% survival in IM injected mice and the lack of hematology, blood chemistry, or histological abnormalities since the maximum tested dose was 40  $\mu$ g. Single intravenous (IV) injections of GNE-lipoplex was lethal in 33% of animals at 100  $\mu$ g dose, while mice injected at 40  $\mu$ g exhibited no toxicity or pathology. This indicates that the maximum tolerated IV dose is somewhere between 40–100  $\mu$ g.

Real-time RT-qPCR analysis demonstrated recombinant human GNE mRNA expression in all muscle tissues that received IM injection of 40  $\mu$ g GNE DNA-lipoplex at 2 weeks post-injection. These results indicate that GNE-lipoplex gene transfer is safe and can produce durable transgene expression in treated muscles.<sup>72</sup>

Another investigation provided evidence that sialylation is essential for the early development of mice and that the inactivation of UDP-GlcNAc 2-epimerase via gene therapy results in early embryonic lethality in mice.<sup>75</sup> This early lethality in the GNE deficient mice is most likely explained by the loss of protection from proteolytic processes or by disturbed cell-cell adhesion because almost all cell adhesion molecules are sialylated glycoproteins.<sup>75</sup> This is evidence that functional GNE enzyme and sialic acid are both necessary for mice and humans.

The same investigators then looked at how the GNE deficient mice differed from wild-type species. Previous evidence showed that GNE-deficiency, on average, was lethal at day 8.5 of embryonic development.<sup>76</sup> Similar to Malicdan, the sialic acid levels of key organs were taken to differentiate between the



sialylation of GNE-deficient and wild-type species.<sup>76</sup> Again, wild type mice had a greater expression of sialic acid in every organ except the kidney. Overall, in GNE-deficient mice, there was a 25% reduction in membrane-bound sialic acids.<sup>76</sup> Studies involving HIBM2 patients demonstrated reduced sialylation on neural cell adhesion molecule (NCAM)<sup>11</sup> and  $\alpha$ -dystroglycan<sup>9</sup> in muscle tissues.

## Discussion

Until recently, little hope for recovery of muscle function has existed for patients with HIBM2. However with the advent of molecular biology and characterization of etiologic pathology, particularly involving the GNE gene; GNE gene replacement may provide an opportunity to better characterize the pathology of this rare disease and to provide possible therapeutic value to patients. Continued development of relevant animal models may facilitate such studies. Clinical investigation of intravenous administration of GNE plasmid—lipoplex product is a fruitful area of research. The rarity of this syndrome and the lack of existing therapeutics allow for the pursuit of an orphan drug development program if safety and evidence of benefit to afflicted patients are demonstrated. Other delivery vehicles may also be considered and tested to enhance activity. Furthermore, once functional GNE expression is augmented in patients (and muscle function improved), it may provide further insight into involvement of other downstream effector pathways. Exploring the expression of molecular signaling patterns of skeletal muscles in parents of early stage and late stage HIBM2 patients to better understand the mechanism of the onset of this disease may enable early preventive approaches to be implemented.

## Acknowledgments

The authors would like to acknowledge Brenda Marr and Susan Mill for their competent and knowledgeable assistance in the preparation of this review.

## Disclosures

The authors report no conflicts of interest.

## References

- Mizusawa H, Kurisaki H, Takatsu M, et al. Rimmed vacuolar distal myopathy: a clinical, electrophysiological, histopathological and computed tomographic study of seven cases. *Journal of Neurology*. 1987;234(3):129–36.
- Sadeh M, Gadoth N, Hadar H, Ben-David E. Vacuolar myopathy sparing the quadriceps. *Brain*. 1993;116 (Pt 1):217–32.
- Argov Z, Yarom R. “Rimmed vacuole myopathy” sparing the quadriceps. A unique disorder in Iranian Jews. *J Neurol Sci*. 1984;64(1):33–43.
- Kim BJ, Ki CS, Kim JW, Sung DH, Choi YC, Kim SH. Mutation analysis of the GNE gene in Korean patients with distal myopathy with rimmed vacuoles. *Journal of Human Genetics*. 2006;51(2):137–40.
- Broccolini A, Ricci E, Cassandrini D, et al. Novel GNE mutations in Italian families with autosomal recessive hereditary inclusion-body myopathy. *Hum Mutat*. 2004;23(6):632.
- Massa R, Weller B, Karpati G, Shoubridge E, Carpenter S. Familial inclusion body myositis among Kurdish-Iranian Jews. *Arch Neurol*. 1991;48(5):519–22.
- Noguchi S, Keira Y, Murayama K, et al. Reduction of UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase activity and sialylation in distal myopathy with rimmed vacuoles. *J Biol Chem*. 2004;279(12):11402–7.
- Penner J, Mantey LR, Elgavish S, et al. Influence of UDP-GlcNAc 2-epimerase/ManNAc kinase mutant proteins on hereditary inclusion body myopathy. *Biochemistry*. 2006;45(9):2968–77.
- Huizing M, Rakocevic G, Sparks SE, et al. Hypoglycosylation of alpha-dystroglycan in patients with hereditary IBM due to GNE mutations. *Mol Genet Metab*. 2004;81(3):196–202.
- Kepler OT, Hinderlich S, Langner J, Schwartz-Albiez R, Reutter W, Pawlita M. UDP-GlcNAc 2-epimerase: a regulator of cell surface sialylation. *Science*. 1999;284(5418):1372–6.
- Ricci E, Broccolini A, Gidaro T, et al. NCAM is hyposialylated in hereditary inclusion body myopathy due to GNE mutations. *Neurology*. 2006;66(5):755–8.
- Langer GA. The structure and function of the myocardial cell surface. *The American Journal of Physiology*. 1978;235(5):H461–8.
- Saito F, Tomimitsu H, Arai K, et al. A Japanese patient with distal myopathy with rimmed vacuoles: missense mutations in the epimerase domain of the UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase (GNE) gene accompanied by hyposialylation of skeletal muscle glycoproteins. *Neuromuscul Disord*. 2004;14(2):158–61.
- Hinderlich S, Salama I, Eisenberg I, et al. The homozygous M712T mutation of UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase results in reduced enzyme activities but not in altered overall cellular sialylation in hereditary inclusion body myopathy. *FEBS Letters*. 2004;566(1–3):105–9.
- Salama I, Hinderlich S, Shlomai Z, et al. No overall hyposialylation in hereditary inclusion body myopathy myoblasts carrying the homozygous M712T GNE mutation. *Biochem Biophys Res Commun*. 2005;328(1):221–6.
- Tajima Y, Uyama E, Go S, et al. Distal myopathy with rimmed vacuoles: impaired O-glycan formation in muscular glycoproteins. *Am J Pathol*. 2005;166(4):1121–30.
- Eisenberg I, Grabov-Nardini G, Hochner H, et al. Mutations spectrum of GNE in hereditary inclusion body myopathy sparing the quadriceps. *Hum Mutat*. 2003;21(1):99.
- Argov Z, Eisenberg I, Grabov-Nardini G, et al. Hereditary inclusion body myopathy: the Middle Eastern genetic cluster. *Neurology*. 2003;60(9):1519–23.
- Sunohara N, Nonaka I, Kamei N, Satoyoshi E. Distal myopathy with rimmed vacuole formation. A follow-up study. *Brain*. 1989;112 (Pt 1):65–83.
- Krause S, Schlotter-Weigel B, Walter MC, et al. A novel homozygous missense mutation in the GNE gene of a patient with quadriceps-sparing hereditary inclusion body myopathy associated with muscle inflammation. *Neuromuscul Disord*. 2003;13(10):830–4.
- Alberts B, Bray D, Lewis J, Raff, Roberts K, Watson J. *Molecular Biology of the cell*. 3rd ed. New York: London: Garland; 1994c.
- Huizing M, Hermos CR, Vasconcelos OM, et al. Pr# 47: Hereditary Inclusion Body Myopathy due to mutations in the gene for UDP-GlcNAc 2-epimerase/ManNAc kinase. In: American Society of Human Genetics 52nd Annual Assembly; 2002 Oct 15–19; Baltimore, Maryland; 2002.
- Vasconcelos OM, Raju R, Dalakas MC. GNE mutations in an American family with quadriceps-sparing IBM and lack of mutations in s-IBM. *Neurology*. 2002;59(11):1776–9.



24. Seppala R, Lehto VP, Gahl WA. Mutations in the human UDP-N-acetylglucosamine 2-epimerase gene define the disease sialuria and the allosteric site of the enzyme. *American Journal of Human Genetics*. 1999;64(6):1563–9.
25. Langer GA. Binding and movement of calcium in the myocardial cell. *Advances in Myocardiology*. 1982;3:265–71.
26. Marengo FD, Wang SY, Wang B, Langer GA. Dependence of cardiac cell  $Ca^{2+}$  permeability on sialic acid-containing sarcolemmal gangliosides. *Journal of Molecular and Cellular Cardiology*. 1998;30(1):127–37.
27. Pasternak C, Wong S, Elson EL. Mechanical function of dystrophin in muscle cells. *The Journal of Cell Biology*. 1995;128(3):355–61.
28. Bennett ES. Isoform-specific effects of sialic acid on voltage-dependent  $Na^+$  channel gating: functional sialic acids are localized to the S5-S6 loop of domain I. *The Journal of Physiology*. 2002;538(Pt 3):675–90.
29. Abriel H, Cabo C, Wehrens XH, et al. Novel arrhythmogenic mechanism revealed by a long-QT syndrome mutation in the cardiac  $Na^+$  channel. *Circulation Research*. 2001;88(7):740–5.
30. Bennett PB, Yazawa K, Makita N, George AL Jr. Molecular mechanism for an inherited cardiac arrhythmia. *Nature*. 1995;376(6542):683–5.
31. Meadows LS, Malhotra J, Loukas A, et al. Functional and biochemical analysis of a sodium channel beta1 subunit mutation responsible for generalized epilepsy with febrile seizures plus type 1. *J Neurosci*. 2002;22(24):10699–709.
32. Spanpanato J, Escayg A, Meisler MH, Goldin AL. Generalized epilepsy with febrile seizures plus type 2 mutation W1204R alters voltage-dependent gating of  $Na^+$ 1.1 sodium channels. *Neuroscience*. 2003;116(1):37–48.
33. Splawski I, Timothy KW, Tateyama M, et al. Variant of SCN5A sodium channel implicated in risk of cardiac arrhythmia. *Science*. 2002;297(5585):1333–6.
34. Wallace RH, Wang DW, Singh R, et al. Febrile seizures and generalized epilepsy associated with a mutation in the  $Na^+$ -channel beta1 subunit gene SCN1B. *Nature Genetics*. 1998;19(4):366–70.
35. Wang Q, Shen J, Splawski I, et al. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. *Cell*. 1995;80(5):805–11.
36. Fozzard HA, Hanck DA. Structure and function of voltage-dependent sodium channels: comparison of brain II and cardiac isoforms. *Physiological Reviews*. 1996;76(3):887–926.
37. Marban E, Yamagishi T, Tomaselli GF. Structure and function of voltage-gated sodium channels. *The Journal of Physiology*. 1998;508(Pt 3):647–57.
38. Catterall WA. From ionic currents to molecular mechanisms: the structure and function of voltage-gated sodium channels. *Neuron*. 2000;26(1):13–25.
39. Schmidt JW, Catterall WA. Palmitoylation, sulfation, and glycosylation of the alpha subunit of the sodium channel. Role of post-translational modifications in channel assembly. *The Journal of Biological Chemistry*. 1987;262(28):13713–23.
40. Miller JA, Agnew WS, Levinson SR. Principal glycopeptide of the tetrodotoxin/saxitoxin binding protein from *Electrophorus electricus*: isolation and partial chemical and physical characterization. *Biochemistry*. 1983;22(2):462–70.
41. Roberts RH, Barchi RL. The voltage-sensitive sodium channel from rabbit skeletal muscle. Chemical characterization of subunits. *The Journal of Biological Chemistry*. 1987;262(5):2298–303.
42. Recio-Pinto E, Thornhill WB, Duch DS, Levinson SR, Urban BW. Neuraminidase treatment modifies the function of electroplax sodium channels in planar lipid bilayers. *Neuron*. 1995;5(5):675–84.
43. Bennett E, Urcan MS, Tinkle SS, Koszowski AG, Levinson SR. Contribution of sialic acid to the voltage dependence of sodium channel gating. A possible electrostatic mechanism. *The Journal of General Physiology*. 1997;109(3):327–43.
44. Zhang Y, Hartmann HA, Satin J. Glycosylation influences voltage-dependent gating of cardiac and skeletal muscle sodium channels. *The Journal of Membrane Biology*. 1999;171(3):195–207.
45. Tyrrell L, Renganathan M, Dib-Hajj SD, Waxman SG. Glycosylation alters steady-state inactivation of sodium channel Nav1.9/NaN in dorsal root ganglion neurons and is developmentally regulated. *J Neurosci*. 2001;21(24):9629–37.
46. Johnson D, Montpetit ML, Stocker PJ, Bennett ES. The sialic acid component of the beta1 subunit modulates voltage-gated sodium channel function. *The Journal of Biological Chemistry*. 2004;279(43):44303–10.
47. James WM, Agnew WS. Alpha-(2–8)-polysialic acid immunoreactivity in voltage-sensitive sodium channel of eel electric organ. *Proc R Soc Lond B Biol Sci*. 1989;237(1287):233–45.
48. Cohen SA, Levitt LK. Partial characterization of the rH1 sodium channel protein from rat heart using subtype-specific antibodies. *Circulation Research*. 1993;73(4):735–42.
49. Chiamvimonvat N, Perez-Garcia MT, Tomaselli GF, Marban E. Control of ion flux and selectivity by negatively charged residues in the outer mouth of rat sodium channels. *The Journal of Physiology*. 1996;491(Pt 1):51–9.
50. Terlau H, Heinemann SH, Stuhmer W, et al. Mapping the site of block by tetrodotoxin and saxitoxin of sodium channel II. *FEBS letters*. 1991;293(1–2):93–6.
51. Ritchie JM. Sodium-channel turnover in rabbit cultured Schwann cells. *Proc R Soc Lond B Biol Sci*. 1988;233(1273):423–30.
52. Zona C, Eusebi F, Milei R. Glycosylation is required for maintenance of functional voltage-activated channels in growing neocortical neurons of the rat. *Proc R Soc Lond B Biol Sci*. 1990;239(1295):119–27.
53. Waechter CJ, Schmidt JW, Catterall WA. Glycosylation is required for maintenance of functional sodium channels in neuroblastoma cells. *The Journal of Biological Chemistry*. 1983;258(8):5117–23.
54. Amsili S, Shlomai Z, Levitzki R, et al. Characterization of hereditary inclusion body myopathy myoblasts: possible primary impairment of apoptotic events. *Cell Death and Differentiation*. 2007;14(11):1916–24.
55. Wang Z, Sun Z, Li AV, Yarema KJ. Roles for UDP-GlcNAc 2-epimerase/ManNAc 6-kinase outside of sialic acid biosynthesis: modulation of sialyltransferase and BiP expression, GM3 and GD3 biosynthesis, proliferation, and apoptosis, and ERK1/2 phosphorylation. *The Journal of Biological Chemistry*. 2006;281(37):27016–28.
56. Eisenberg I, Thiel C, Levi T, et al. Fine-structure mapping of the hereditary inclusion body myopathy locus. *Genomics*. 1999;55(1):43–8.
57. Takahashi C, Sheng Z, Horan TP, et al. Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. Proceedings of the National Academy of Sciences of the United States of America. 1998;95(22):13221–6.
58. Eisenberg I, Avidan N, Potikha T, et al. The UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase gene is mutated in recessive hereditary inclusion body myopathy. *Nature Genetics*. 2001;29(1):83–7.
59. Broccolini A, Gidaro T, Morosetti R, et al. Nephrylin participates in skeletal muscle regeneration and is accumulated in abnormal muscle fibres of inclusion body myositis. *Journal of Neurochemistry*. 2006;96(3):777–89.
60. Amsili S, Zer H, Hinderlich S, et al. UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase (GNE) binds to alpha-actinin 1: novel pathways in skeletal muscle? *PLoS ONE*. 2008;3(6):e2477.
61. Krause S, Hinderlich S, Amsili S, et al. Localization of UDP-GlcNAc 2-epimerase/ManNAc kinase (GNE) in the Golgi complex and the nucleus of mammalian cells. *Experimental Cell Research*. 2005;304(2):365–79.
62. Savelkoul PJ, Manoli I, Sparks SE, et al. Normal sialylation of serum N-linked and O-GalNAc-linked glycans in hereditary inclusion-body myopathy. *Molecular Genetics and Metabolism*. 2006;88(4):389–90.
63. Krause S, Aleo A, Hinderlich S, et al. GNE protein expression and subcellular distribution are unaltered in HIBM. *Neurology*. 2007;69(7):655–9.
64. Dalakas MC. Polymyositis, dermatomyositis and inclusion-body myositis. *The New England Journal of Medicine*. 1999;325(21):1487–98.
65. Oldfors A, Lindberg C. Inclusion body myositis. *Curr Opin Neurol*. 1999;12(5):527–33.
66. Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K. Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. *Neurology*. 1997;48(3):712–6.
67. Sparks S, Rakocevic G, Joe G, et al. Intravenous immune globulin in hereditary inclusion body myopathy: a pilot study. *BMC Neurology*. 2007;7:3.
68. Dalakas MC, Koffman B, Fujii M, Spector S, Sivakumar K, Cupler E. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of ibm. *Neurology*. 2001;56(3):323–7.



69. Sparks SE, Ciccone C, Lator M, et al. Use of a cell-free system to determine UDP-N-acetylglucosamine 2-epimerase and N-acetylmannosamine kinase activities in human hereditary inclusion body myopathy. *Glycobiology*. 2005;15(11):1102–10.
70. Malicdan MC, Noguchi S, Nonaka I, Hayashi YK, Nishino I. A Gne knockout mouse expressing human D176V mutation develops features similar to distal myopathy with rimmed vacuoles or hereditary inclusion body myopathy. *Hum Mol Genet*. 2007;16(2):115–28.
71. Galeano B, Klootwijk R, Manoli I, et al. Mutation in the key enzyme of sialic acid biosynthesis causes severe glomerular proteinuria and is rescued by N-acetylmannosamine. *The Journal of Clinical Investigation*. 2007;117(6):1585–94.
72. Phadke AP, Jay C, Chen SJ, et al. Safety and in vivo expression of a GNE-transgene: A novel treatment approach for Hereditary Inclusion Body Myopathy-2. (Submitted).
73. Jay C, Nemunaitis G, Nemunaitis J, et al. Preclinical Assessment of wt GNE Gene Plasmid for Management of Hereditary Inclusion Body Myopathy 2 (HIBM2). *Gene Regulation and Systems Biology*. 2008;2:243–52.
74. Templeton NS, Lasic DD, Frederik PM, Strey HH, Roberts DD, Pavlakis GN. Improved DNA: liposome complexes for increased systemic delivery and gene expression. *Nature Biotechnology*. 1997;15(7):647–52.
75. Schwarzkopf M, Knobeloch KP, Rohde E, et al. Sialylation is essential for early development in mice. *Proceedings of the National Academy of Sciences of the United States of America*. 2002;99(8):5267–70.
76. Gagiannis D, Orthmann A, Danssmann I, Schwarzkopf M, Weidemann W, Horstkorte R. Reduced sialylation status in UDP-N-acetylglucosamine-2-epimerase/N-acetylmannosamine kinase (GNE)-deficient mice. *Glycoconjugate Journal*. 2007;24(2–3):125–30.

**Publish with Libertas Academica and every scientist working in your field can read your article**

*“I would like to say that this is the most author-friendly editing process I have experienced in over 150 publications. Thank you most sincerely.”*

*“The communication between your staff and me has been terrific. Whenever progress is made with the manuscript, I receive notice. Quite honestly, I’ve never had such complete communication with a journal.”*

*“LA is different, and hopefully represents a kind of scientific publication machinery that removes the hurdles from free flow of scientific thought.”*

**Your paper will be:**

- Available to your entire community free of charge
- Fairly and quickly peer reviewed
- Yours! You retain copyright

**<http://www.la-press.com>**